IVRA

Serial Number 98747709
730

Registration Progress

Application Filed
Sep 12, 2024
Under Examination
Jun 3, 2025
Approved for Publication
Apr 8, 2025
Published for Opposition
Apr 8, 2025
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Jun 03, 2026 329 days

Trademark Image

IVRA

Basic Information

Serial Number
98747709
Deadline
June 3, 2026
Description
Statement of Use or 2nd Extension Due
Filing Date
September 12, 2024
Published for Opposition
April 8, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Jul 2, 2025
Application
Pending
Classes
005

Rights Holder

Apotex Inc.

03
Address
150 Signet Drive
Toronto, Ontario M9L1T9
CA

Ownership History

Apotex Inc.

Original Applicant
03
Toronto, Ontario CA

Apotex Inc.

Owner at Publication
03
Toronto, Ontario CA

Legal Representation

Attorney
Jessica G. Kraver

USPTO Deadlines

Next Deadline
329 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
June 03, 2026
Extension Available
Until June 03, 2026

Application History

13 events
Date Code Type Description
Jul 3, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2025 EXT1 S SOU EXTENSION 1 FILED
Jul 2, 2025 EX1G S SOU EXTENSION 1 GRANTED
Jul 2, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 2, 2025 EISU I TEAS STATEMENT OF USE RECEIVED
Jun 3, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 8, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 8, 2025 PUBO A PUBLISHED FOR OPPOSITION
Apr 2, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 13, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2025 DOCK D ASSIGNED TO EXAMINER
Sep 12, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 12, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparation for palliative treatment of patients with multiple myeloma

Classification

International Classes
005